SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-101445
Filing Date
2020-09-01
Accepted
2020-09-01 17:02:17
Documents
14
Period of Report
2020-09-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2029923-3_8k.htm   iXBRL 8-K 29347
2 EXHIBIT 5.1 tm2029923d3_ex5-1.htm EX-5.1 20109
6 GRAPHIC tm2029923d3_ex5-1img01.jpg GRAPHIC 3954
  Complete submission text file 0001104659-20-101445.txt   237397

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20200901.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20200901_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20200901_pre.xml EX-101.PRE 22708
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2029923-3_8k_htm.xml XML 3745
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 201154963
SIC: 2834 Pharmaceutical Preparations